Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu
AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first
AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just
Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting 'asset-centric' companies at all stages of
MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho